Skip to main content
    T

    TransMedics Group Inc (TMDX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $75.52
    -3.61 (-4.57%)

    Market Cap: $2.62B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(18/30)
    Avg Surprise
    +136.47%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.29
    Range$0.15 - $0.40
    10 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.43-31.4%
    60d ago$0.33-10.8%
    30d ago$0.30-1.7%
    7d ago$0.29+2.1%
    Current$0.29
    Revenue Consensus
    $178M
    Range$170M - $188M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.13
    Range$-0.21 - $0.25
    10 analysts
    Revenue Consensus
    $206M
    Range$192M - $217M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.13---
    Sep 26EST
    		-$0.29---
    Jun 26
    Reported Aug 4
    		$0.44$0.50-12.00%Miss-52.2%
    Mar 26
    Reported May 5
    		$0.30N/A-50.82%Miss-57.1%
    Dec 25
    Reported Feb 24
    		$0.05N/A-86.94%Miss-73.2%
    Sep 25
    Reported Oct 29
    		$0.66$0.36+83.33%Beat+450.0%
    Jun 25
    Reported Jul 30
    		$0.92$0.43+113.95%Beat+162.9%
    Mar 25
    Reported May 8
    		$0.70$0.24+191.67%Beat+100.0%
    Dec 24
    Reported Feb 27
    		$0.19$0.22-13.64%Miss+58.3%
    Sep 24
    Reported Oct 28
    		$0.12N/A-62.50%Miss+71.4%
    Jun 24
    Reported Jul 31
    		$0.35$0.20+75.00%Beat+1266.7%
    Mar 24
    Reported Apr 30
    		$0.35$0.01+3400.00%Beat+537.5%
    Dec 23
    Reported Feb 26
    		$0.12$-0.03+500.00%Beat+157.1%
    Sep 23
    Reported Nov 6
    		$0.07$-0.13+153.85%Beat+128.0%
    Jun 23
    Reported Aug 3
    		$-0.03N/A+76.92%Beat+92.7%
    Mar 23
    Reported May 1
    		$-0.08N/A+66.67%Beat+78.9%
    Dec 22
    Reported Feb 22
    		$-0.21$-0.30+30.00%Beat+54.3%
    Sep 22
    Reported Nov 3
    		$-0.25$-0.41+39.02%Beat+46.8%
    Jun 22
    Reported Aug 1
    		$-0.41$-0.34-20.59%Miss-5.1%
    Mar 22
    Reported May 3
    		$-0.38$-0.39+2.56%Beat-31.0%
    Dec 21
    Reported Feb 23
    		$-0.46$-0.42-9.52%Miss-100.0%
    Sep 21
    Reported Nov 9
    		$-0.47$-0.37-27.03%Miss-147.4%
    Jun 21
    Reported Aug 5
    		$-0.39$-0.29-34.48%Miss-8.3%
    Mar 21
    Reported May 4
    		$-0.29$-0.30+3.33%Beat+31.0%
    Dec 20
    Reported Mar 2
    		$-0.23$-0.25+8.00%Beat+46.5%
    Sep 20
    Reported Nov 4
    		$-0.19$-0.33+42.42%Beat+51.3%
    Jun 20
    Reported Aug 5
    		$-0.36$-0.45+20.00%Beat+18.2%
    Mar 20
    Reported May 6
    		$-0.42$-0.40-5.00%Miss+91.4%
    Dec 19
    Reported Mar 2
    		$-0.43$-0.40-7.50%Miss+59.0%
    Sep 19
    Reported Nov 6
    		$-0.39$-0.45+13.33%Beat-56.0%
    Jun 19
    Reported Aug 7
    		$-0.44$-0.44+0.00%Beat-
    Mar 19
    Reported May 2
    		$-4.86$-0.98-395.92%Miss-
    Dec 18
    Reported Feb 27
    		$-1.05$0.00N/AMiss-
    Sep 18
    Reported Dec 12
    		$-0.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio52.05EV/EBITDA23.04x
    Price/FCF33.04xFCF Yield3.03%
    Profitability
    Profit Margin22.70%Operating Margin12.50%
    ROE36.30%ROIC6.80%
    Financial Health
    Debt/Equity1.66xInterest Coverage4.42x
    Current Ratio6.62xQuick Ratio6.07x
    Trading Statistics
    Beta1.93Avg Volume771.54K
    52-Week High$156.0052-Week Low$60.10

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$79.25
    SMA 20$82.37
    SMA 50$85.62
    SMA 200$98.13
    EMA 10$79.38
    EMA 20$81.39
    EMA 50$82.88
    EMA 200$92.59

    MACD

    Line: -2.20Signal: -1.58Hist: -0.62

    ADX

    ADX: 13.0+DI: 16.3-DI: 23.3

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down100.0
    PSAR$86.08

    Bollinger Bands

    Upper Band$89.79
    Lower Band$74.95
    %B Position1802%(Upper)
    Band Width0.04

    RSI (14-Day)

    Neutral
    36.3

    Momentum Oscillators

    Stoch %K13.5
    Stoch %D12.9
    Williams %R-94.1
    ROC (10d)-9.5%
    Momentum-7.93
    CCI (20d)-138.5
    MFI (14d)39.7

    Volatility Measures

    ATR (14d)$3.87(5.1%)
    StdDev (20d)3.71
    Hist Vol39.3%(Moderate)

    Volume Flow

    VWAP$76.24
    OBV-7.1M
    AD Line-8.3M
    CMF (20d)-0.092

    Volume Metrics

    Avg Vol (20d)778.3K
    Vol Ratio1.1x
    VWMA (20d)$82.18

    Pivot Points

    R3$82.97
    R2$81.69
    R1$80.41
    Pivot Point$79.14
    S1$77.86
    S2$76.58
    S3$75.30

    Advanced Oscillators

    TSI-16.71
    Ultimate Osc34.8
    KST-89.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$189.95M$173.93M$160.76M$143.82M$157.37M$143.54M$121.62M$108.76M$114.31M$96.85M$81.17M$66.43M
    Cost of Revenue$76.75M$72.77M$67.35M$59.25M$60.78M$55.31M$49.61M$47.92M$45.04M$36.89M$33.25M$25.77M
    Gross Profit$113.20M$101.16M$93.41M$84.58M$96.59M$88.23M$72.01M$60.84M$69.26M$59.96M$47.92M$40.66M
    Operating Expenses$89.46M$87.86M$72.14M$61.27M$60.02M$60.78M$63.37M$56.92M$56.75M$47.54M$45.32M$69.00M
    R&D$31.63M$24.88M$20.70M$15.26M$15.93M$17.16M$16.46M$14.27M$13.86M$11.38M$10.76M$38.34M
    SG&A$57.83M$62.98M$51.44M$46.02M$44.09M$43.63M$46.91M$42.66M$42.90M$36.16M$34.56M$30.65M
    Operating Income$23.74M$13.30M$21.27M$23.30M$36.57M$27.44M$8.64M$3.92M$12.51M$12.42M$2.60M$-28,335,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$7.22M$7.17M$3.35M$3.49M$3.48M$3.46M$3.57M$3.62M$3.62M$3.60M$3.60M$3.59M
    Income Before Tax$19.41M$8.48M$21.63M$23.03M$36.18M$26.68M$6.99M$4.25M$12.15M$12.39M$3.86M$-26,929,000
    Income Tax Expense$4.72M$1.17M$-83,750,000$-1,288,000$1.27M$994,000$132,000$29,000$-41,000$196,000$-168,000$-1,507,000
    Net Income$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M$4.22M$12.19M$12.20M$4.03M$-25,422,000
    EBITDA$36.87M$27.52M$32.45M$33.37M$46.39M$36.27M$16.24M$13.04M$20.38M$20.29M$11.07M$-21,446,000
    EBIT$26.63M$15.65M$24.99M$26.52M$39.66M$30.14M$10.56M$7.86M$15.78M$15.99M$7.47M$-23,339,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

    Quality meets catalyst: Two regulatory wins in 5 days. Dupixent's AFRS approval + garetosmab Priority Review. Quality Score 98/100. The business is strengthening while the stock trades near fair value. The honest valuation: At $789...

    Glenn Ford
    •
    2/27/26
    •
    177
    Biotech, BioPharma
    Also mentions:
    SNYAMGNTMDXGILD

    Part 2 of 3: The Night the Organ Monopoly Proved It Was Real

    Tonight's earnings confirmed the thesis: Q4 revenue $160.8M (+32%), FY $605.5M (+37%), 5,139 OCS cases (+38%), 2026 guidance $727M–$757M. TMDX has graduated from speculative disruptor to verified logistics monopoly. The 22-aircraft fleet is the moat...

    Glenn Ford
    •
    2/25/26
    •
    147
    healthcare-innovation, Healthcare Stocks
    Also mentions:
    GILDREGN

    Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To

    Gilead's $14.3B Biktarvy franchise grew 7% YoY in 2025, proving HIV isn't ex-growth. Total revenues hit $29.4B. The base business alone justifies ~$150 fair value. Yeztugo (twice-yearly HIV prevention) expands TAM from diagnosed patients to at-risk populations. FDA approved June 2025. $800M combined...

    Glenn Ford
    •
    2/24/26
    •
    139
    Healthcare Stocks, healthcare-innovation
    Also mentions:
    TMDXREGNJNJ

    Why TransMedics Stock is a Buy for Long-Term Investors

    TransMedics is replacing a 60-year-old organ-transport method with its FDA-approved OCS platform, which keeps hearts, lungs, and livers alive and functioning during transit — a massive step-change in reliability and outc Business model now prints cash...

    Glenn Ford
    •
    11/14/25
    •
    285
    medical-technology, healthcare-innovation, organ-transplant, growth-stocks
    Also mentions:
    ISRGSYKMDTABTEW

    TMDX Valuation and Fair Value

    P/E
    52.0x
    Forward P/E
    37.3x
    EV/EBITDA
    23.0x
    P/FCF
    33.0x
    PEG
    0.8x
    P/B
    5.0x
    See GNG's fair value

    TMDX Profitability: Margins, ROIC and FCF

    Gross margin
    58.7%
    Operating margin
    12.5%
    Net margin
    22.7%
    ROIC
    6.8%
    ROE
    36.3%
    FCF margin
    11.8%
    FCF yield
    3.0%

    TMDX Competitors

    CompanyTicker
    Precigen IncPGEN
    Nurix Therapeutics IncNRIX
    Neogen CorporationNEOG
    Guardian Pharmacy Services, Inc.GRDN
    Aveanna Healthcare Holdings IncAVAH
    Clover Health Investments CorpCLOV
    Privia Health Group IncPRVA
    Zai Lab LtdZLAB

    Sector: Healthcare

    TMDX Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    6
    Hold
    4
    Sell
    0
    Strong Sell
    0

    TMDX Bull Case vs Bear Case

    Bull case

    • TMDX has a 22.7% net profit margin.
    • TMDX grew quarterly revenue 20.7% year over year.
    • 66.7% of TMDX's analyst ratings are Buy or Strong Buy.

    Bear case

    • TMDX trades at 52.0x trailing earnings.
    • TMDX beat EPS estimates in 37.5% of its last 8 reported quarters.

    TMDX Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    20.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.29
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 2 down

    Frequently Asked Questions About TMDX

    Does TMDX pay dividends?

    TransMedics Group Inc (TMDX) does not currently pay a regular dividend.

    What is TMDX's P/E ratio?

    TransMedics Group Inc has a price-to-earnings (P/E) ratio of 52.05.

    What is TMDX's market cap?

    TransMedics Group Inc (TMDX) has a market capitalization of $2.62B with a current stock price of $75.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In